Acorda Therapeutics

Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The company is engaged in the commercial sales of Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Also, the company markets branded Ampyra (dalfampridine), an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP) approved to improve walking in adults with multiple sclerosis.
  • TickerACOR
  • ISINUS00484M1062
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Wedbush Research

Wedbush Morning Call - Jul 13 2020 6:44AM

Kenneth Shields ...
  • Laura Chico

Neurology Prescription Sales Tracker -- Week Ending 7/3/20

Kenneth Shields ...
  • Laura Chico

Neurology Prescription Sales Tracker -- Week Ending 6/26/20

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Biotechs are breaking out. XBI and IBB ETF's are bullish. • Homebuilders appear to be staging near-term reversals in price and RS. • Railroads continue to lead in the Transportation Sector. Many truckers are reversing near-term downtrends. • A few Consumer Staples equities are staging price and RS reversals. (Example POST)

Dave Nicoski

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

Shelley Moen

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

Shelley Moen

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

Wedbush Research

Wedbush Morning Call - Jul 13 2020 6:44AM

Kenneth Shields ...
  • Laura Chico

Neurology Prescription Sales Tracker -- Week Ending 7/3/20

Kenneth Shields ...
  • Laura Chico

Neurology Prescription Sales Tracker -- Week Ending 6/26/20

ACORDA THERP.INCO. sees an upgrade to Slightly Negative thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to ACORDA THERP.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date June 9, 2020, the closing price was USD 0.97 and its target price was estimated at USD 0.28.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch